Moderna appoints Jorge Gomez as CFO; David Meline to retire effective May 9, 2022

Moderna, Inc.

Jorge Gomez appointed CFO effective May 9, 2022, reporting to CEO Stéphane Bancel.
Gomez previously CFO at Dentsply Sirona (Nasdaq: XRAY) and held CFO roles at Cardinal Health.
Current CFO David Meline retiring; will serve as consultant through July 2024 with continued equity vesting.
Gomez receives $700k base salary, $500k signing bonus, and equity grant valued at $4M vesting over four years.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Jorge M. Gomez

Chief Financial Officer

MRNA · Moderna, Inc.

Effective: 2022-05-09
Filed: April 11, 2022, 7:59 PM ET

On April 11, 2022, Moderna, Inc. (the “Company”) announced that Jorge M. Gomez had been appointed to serve as the Company’s Chief Financial Officer (“CFO”), beginning May 9, 2022.

Departed

David Meline

Chief Financial Officer

MRNA · Moderna, Inc.

Effective: 2022-05-09
Successor: Jorge M. Gomez
Filed: April 11, 2022, 7:59 PM ET

Following the appointment of Mr. Gomez, David Meline will retire as the Company’s CFO effective the same date, but will remain as a consultant to the Company to assist with the transition.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Jorge M. Gomez was appointed as Chief Financial Officer at Moderna, Inc..

Action: appointed
Role: Chief Financial Officer

Exact text from the filing

On April 11, 2022, Moderna, Inc. (the “Company”) announced that Jorge M. Gomez had been appointed to serve as the Company’s Chief Financial Officer (“CFO”), beginning May 9, 2022.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

David Meline retired as Chief Financial Officer at Moderna, Inc..

Action: retired
Role: Chief Financial Officer

Exact text from the filing

Following the appointment of Mr. Gomez, David Meline will retire as the Company’s CFO effective the same date, but will remain as a consultant to the Company to assist with the transition.

View on SEC.gov

Moderna, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-101074

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.